|
- 2019
Single dose of DPX-rPA, an enhanced-delivery anthrax vaccine formulation, protects against a lethal Bacillusanthracis spore inhalation challengeDOI: 10.1038/s41541-019-0102-z Abstract: Single-dose delivery of DPX-rPA (recombinant protective antigen) in mice induces rapid and sustained anti-rPA immunoglobulin G (IgG) response. Groups of nine CD-1 mice were vaccinated (intramuscularly (i.m.)) once with DPX-rPA dosed at either 10?μg (purple circles), 4?μg (gray squares), 2?μg (green diamonds), 0.5?μg (dark purple downwards triangles), or 0.05?μg (orange upwards triangles) or once with 10?μg alum-rPA control vaccine (black x). Immunizations are indicated with arrows. Endpoint anti-rPA IgG titers, presented as Log10 values, at Weeks 3, 4, 8, 12, 16, and 20 post immunization determined by enzyme-linked immunosorbent assay (ELISA) using plates coated with rPA antigen. Results are shown as mean?±?SEM. Significance shown was determined by two-way analysis of variance (ANOVA) with Tukey’s multiple comparisons test of at least p?<?0.05, on Weeks 3, 4, 8 and 20: *, DPX-rPA (0.05?μg) compared to DPX-rPA (2, 4, 10?μg), DPX-rPA (0.5?μg) vs. DPX-rPA (4, 10?μg); +, DPX-rPA (0.05?μg) vs. DPX-rPA (2, 4, 10?μg), DPX-rPA (0.5?μg) vs. DPX-rPA (2, 4, 10?μg); ?, DPX-rPA (0.05?μg) vs. DPX-rPA (2, 4, 10?μg), and alum, DPX-rPA (0.5?μg) vs. DPX-rPA (2, 4, 10?μg) and alum, DPX-rPA (2?μg) vs. DPX-rPA (10?μg), DPX-rPA (4?μg) vs. DPX-rPA (10?μg), DPX-rPA (10?μg) vs. alum; φ, DPX-rPA (0.05?μg) vs. all other groups, DPX-rPA (0.5?μg) vs. DPX-rPA (μg), DPX-rPA (2?μg) vs. DPX-rPA (10?μg), DPX-rPA (4?μg) vs. DPX-rPA (10?μg), DPX-rPA (10?μg) vs. alu
|